Unknown

Dataset Information

0

Severity of COVID19 infection among patients with multiple sclerosis treated with interferon-β.

ABSTRACT:

Background

Interferon-β, a disease-modifying therapy (DMT) for MS, may be associated with less severe COVID-19 in people with MS.

Results

Among 5,568 patients (83.4% confirmed COVID-19), interferon-treated patients had lower risk of severe COVID-19 compared to untreated, but not to glatiramer-acetate, dimethyl-fumarate, or pooled other DMTs.

Conclusions

In comparison to other DMTs, we did not find evidence of protective effects of interferon-β on the severity of COVID-19, though compared to the untreated, the course of COVID19 was milder among those on interferon-β. This study does not support the use of interferon-β as a treatment to reduce COVID-19 severity in MS.

SUBMITTER: Simpson-Yap S 

PROVIDER: S-EPMC9310378 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Severity of COVID19 infection among patients with multiple sclerosis treated with interferon-β.

Simpson-Yap Steve S   Pirmani Ashkan A   De Brouwer Edward E   Peeters Liesbet M LM   Geys Lotte L   Parciak Tina T   Helme Anne A   Hillert Jan J   Moreau Yves Y   Edan Gilles G   Spelman Tim T   Sharmin Sifat S   McBurney Robert R   Schmidt Hollie H   Bergmann Arnfin A   Braune Stefan S   Stahmann Alexander A   Middleton Rodden R   Salter Amber A   Bebo Bruce B   van der Walt Anneke A   Butzkueven Helmut H   Ozakbas Serkan S   Karabudak Rana R   Boz Cavit C   Alroughani Raed R   Rojas Juan I JI   van der Mei Ingrid I   Sciascia do Olival Guilherme G   Magyari Melinda M   Alonso Ricardo R   Nicholas Richard R   Chertcoff Anibal A   Zabalza Ana A   Arrambide Georgina G   Nag Nupur N   Descamps Annabel A   Costers Lars L   Dobson Ruth R   Miller Aleisha A   Rodrigues Paulo P   Prčkovska Vesna V   Comi Giancarlo G   Kalincik Tomas T  

Multiple sclerosis and related disorders 20220725

<h4>Background</h4>Interferon-β, a disease-modifying therapy (DMT) for MS, may be associated with less severe COVID-19 in people with MS.<h4>Results</h4>Among 5,568 patients (83.4% confirmed COVID-19), interferon-treated patients had lower risk of severe COVID-19 compared to untreated, but not to glatiramer-acetate, dimethyl-fumarate, or pooled other DMTs.<h4>Conclusions</h4>In comparison to other DMTs, we did not find evidence of protective effects of interferon-β on the severity of COVID-19, t  ...[more]